Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hebei Soho-Yiming Pharmaceuticals is a leading Chinese pharmaceutical company specializing in the development and large-scale synthesis of peptide-based active pharmaceutical ingredients (APIs) and finished drug products. The company has established a comprehensive technology platform for solid-phase and liquid-phase peptide synthesis, allowing it to supply a wide range of critical medications globally. Its portfolio includes key treatments such as oxytocin for postpartum hemorrhage, terlipressin for variceal bleeding, and desmopressin for diabetes insipidus. Soho-Yiming operates state-of-the-art GMP-certified manufacturing facilities and maintains a strong presence in both the domestic Chinese market and international export markets. The company is recognized for its technical expertise in complex peptide chemistry and serves as a vital supplier to the global healthcare industry.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Soho-Yiming Pharmaceuticals.